Navigation Links
Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines
Date:1/24/2011

MANHATTAN BEACH, Calif., Jan. 24, 2011/PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the company's support of the FDA's newly drafted "Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination." This guidance document, designed to encourage companies to collaborate and seek approval for successfully developed drug combinations, would support Genesis Biopharma's development of its anti-CD55 monoclonal antibody shown to have potentially broad application as a targeted cancer therapy.  

In particular, this guidance would help enable the company's goal to form partnerships with pharmaceutical and biotechnology companies and to support clinical development efforts for their anti-CD55 monoclonal antibody.

"Genesis Biopharma's anti-CD55 program has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development," said Robert Brooke, Genesis Biopharma President and CEO. "When this FDA guidance is finalized and approved, it will simplify efforts to form codevelopment partnerships and will ultimately ensure timely access to new and effective treatments for patients fighting currently sub-optimally treated conditions, such as metastatic cancer."  

"The regulatory professionals now have a much needed tool to guide companies when developing combinations of two investigational products toward the much needed goal of making available safe and effective therapies," added Dr. Hana B. Moran of Moran Advisors, LLC.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit '/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genesis Biopharma Raises $845,000 in Private Financings
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. Genesis Biopharma Announces $700K Private Financing
4. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
5. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
6. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
7. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
8. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
9. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
10. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
11. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Coalition to Save Pure, a group of stockholders and director ... replace the current board of directors of Pure Bioscience, Inc. ... statement with the Securities and Exchange Commission. ... antibacterial, antiviral and antifungal technology. In the filing, ...
... LOS ANGELES, Dec. 22, 2011 Thanks to continued ... advocates, the Pacific Meso Center (PMC) announces the opening ... to the discovery of new treatments for malignant pleural ... by asbestos exposure. Pacific Meso Center (PMC) ...
... Life in Science," ASU Foundation Professor and Director of the Origins ... very public modern physicist, has been chosen as the 2011 Book ... Feynman is one of the most famous physicists of the ... bring science to the people, taking time to explain in simple ...
Cached Biology Technology:Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date 2First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles 2Book on Richard Feynman nets honors for Arizona State professor 2Book on Richard Feynman nets honors for Arizona State professor 3
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
(Date:7/9/2014)... announce themselves with pain and fever but often can be ... are sneaky and hard to beat. Now, scientists have built ... tiny DNA pyramids. Published in the journal ACS Applied ... flag bacteria and kill more of them than medicine alone. ... infectious pathogens can lie in wait, undetectable in the human ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... If you,re one of the millions who dread the spring ... in the May 2009 issue of the Journal of ... of American scientists have identified a previously unknown cellular switch ... important, this study also suggests that at least for some ...
... 1918 a human influenza virus known as the Spanish ... swine respiratory disease occurred concurrently. A Kansas State University ... was able to infect and replicate in pigs, but ... like monkeys, mice and ferrets where the infection has ...
... common plant toxins that affect human health and ecosystems ... new study also suggest that smoldering fires may produce ... human exposures to a minimum during controlled burns. ... helps researchers understand how they cycle through earth and ...
Cached Biology News:Just in time for spring: Scientists find the cellular on and off switch for allergies and asthma 2K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses 2Potentially harmful chemicals found in forest fire smoke 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: